The Effect of Silymarin on the Expression of Chemokine Receptors in T Helper 1 (Th1) Cells

Document Type : Original Article (s)

Authors

1 Department of Biology, Payam-e-Noor University, Isfahan, Iran

2 Assistant Professor, Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Department of Biology, Payam-e-Noor University, Isfahan, Iran

Abstract

Background: Silymarin, apolyphenolic flavnoid derived from milk thistle (Silybum marianum), is known to have anti-inflammatory, hepatoprotective, and anticarcinogenic effects. The aim of this study was to investigate the effect of silymarin on the chemokine receptor of (T helper) Th1 cells.Methods: Peripheral blood mononuclear cells (PBMCs) from 8 healthy individuals were activated with Conconavalin 'A' and treated with silymarin (100 µM) or dimethyl sulfoxide (DMSO), as negative control, in a standard condition (RT: 37 and CO2: 5%). Cells were incubated (72 hours) and then examined for the cytometric evaluation of chemokine receptor CXCR3 expression on Th1 cells. Peripheral blood lymphocyte subpopulations were identified and evaluated by two color flow cytometric analysis. A nonparametric paired samples Wilcoxon test was applied to compare the grouped data. Results were expressed as the mean ± standard deviation (SD). P-values < 0·05 were considered to indicate significant differences.Findings: PBMCs treated with silymarin increased the expression of CXCR3 on Th1 cells. These results were significantly (P = 0.017) in all samples.Conclusion: This study provided evidences of effectiveness for silymarine on the expression of CXCR3. Therefore, in future, silymarine could be used instead of other drugs such as immunosuppressive with fewer side effects in autoimmune diseases.

Keywords


  1. Li D, Wang Z, Sun P, Jin Y, Lin DH, Hebert SC, et al. Inhibition of MAPK stimulates the Ca2+-dependent big-conductance K channels in cortical collecting duct. Proc Natl Acad Sci USA 2006; 103(51): 19569-74.
  2. Gazak R, Walterova D, Kren V. Silybin and silymarin--new and emerging applications in medicine. Curr Med Chem 2007; 14(3): 315-38.
  3. Gharagozloo M, Amirghofran Z. Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells. J Cancer Res Clin Oncol 2007; 133(8): 525-32.
  4. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB. Anticancer potential of silymarin: from bench to bed side. Anticancer Res 2006; 26(6B): 4457-98.
  5. Gharagozloo M, Velardi E, Bruscoli S, Agostini M, Di SM, Donato V, et al. Silymarin suppress CD4+ T cell activation and proliferation: effects on NF-kappaB activity and IL-2 production. Pharmacol Res 2010; 61(5): 405-9.
  6. Hussain SA, Jassim NA, Numan IT, Al-Khalifa II, Abdullah TA. Anti-inflammatory activity of silymarin in patients with knee osteoarthritis. A comparative study with piroxicam and meloxicam. Saudi Med J 2009; 30(1): 98-103.
  7. Wilasrusmee C, Kittur S, Shah G, Siddiqui J, Bruch D, Wilasrusmee S, et al. Immunostimulatory effect of Silybum Marianum (milk thistle) extract. Med Sci Monit 2002; 8(11): BR439-BR443.
  8. Lang I, Nekam K, Deak G, Muzes G, Gonzales-Cabello R, Gergely P, et al. Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers. Ital J Gastroenterol 1990; 22(5): 283-7.
  9. Cheung CW, Gibbons N, Johnson DW, Nicol DL. Silibinin--a promising new treatment for cancer. Anticancer Agents Med Chem 2010; 10(3): 186-95.
  10. Rabinovich GA, Ariel A, Hershkoviz R, Hirabayashi J, Kasai KI, Lider O. Specific inhibition of T-cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1. Immunology 1999; 97(1): 100-6.
  11. Sallusto F, Kremmer E, Palermo B, Hoy A, Ponath P, Qin S, et al. Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol 1999; 29(6): 2037-45.
  12. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101(4): 746-54.
  13. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61(3): 246-57.
  14. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187(12): 2009-21.
  15. Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, et al. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology 2010; 138(2): 671-81, 681.